About the Company
Acasti is a biopharmaceutical innovator that has historically focused on the research, development and commercialization of prescription drugs using OM3 fatty acids delivered both as free fatty acids and bound-to-phospholipid esters, derived from krill oil. OM3 fatty acids have extensive clinical evidence of safety and efficacy in lowering triglycerides in patients with hypertriglyceridemia, or HTG. CaPre, an OM3 phospholipid therapeutic, was being developed for patients with severe HTG.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ACST News
Closing Bell: Acasti Pharma Inc up on Monday (ACST)
Today during trading, Acasti Pharma Inc shares closed at $0.58 after opening the day at $0.56. It traded at a low of $0.56 to a high of $0.58. Share prices gained 1.75 percent from the previous day's ...
Acasti Pharma, Inc. Class A Common Stock (ACST)
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green highlights the top performing ETF by % change in the past ...
Acasti Pharma Inc.
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...
Acasti to Participate in the Lytham Partners Spring 2023 Investor Conference
LAVAL, QC, May 17, 2023 /PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (Nasdaq: ACST), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine that ...
Acasti Pharma, Inc. (ACST) stock forecast and price target
Find the latest Acasti Pharma, Inc. ACST analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports.
Acasti Pharma Provides Update on Recent Financing Activities
As required pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST) is providing an update on the use of its “at ...
Acasti Pharma Receives FDA Response to TRILOGY 1 Briefing Package
Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription ...
Acasti Pharma Celebrates Rare Disease Day
LAVAL, Québec, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today recognizes and celebrates Rare Disease Day (February 28), as ...
Closing Bell: Acasti Pharma Inc up on Monday (ACST)
In market activity today, Acasti Pharma Inc opened at $0.56 and closed at $0.58. prices ranged from $0.56 to $0.58. Shares raised 1.75 percent from the previous day's close of $0.57. During the ...
Acasti to Participate in the Lytham Partners Spring 2023 Investor Conference
LAVAL, QC, May 17, 2023 /PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (Nasdaq: ACST), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine that ...
Loading the latest forecasts...